Please assess the completion status of the following clinical trial:

Trial Title: Crofelemer for Functional Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is a man or woman aged 18 to 65 years, inclusive, at Screening.~2. Patient has functional diarrhea defined by the Rome IV criteria as loose (mushy) or watery stools ≥25% and hard or lumpy stools \<25% of bowel movements~3. Patient has had a colonoscopy performed:~   1. Within 10 years prior to Prescreening if patient is at least 50 years of age (alternatively, a flexible sigmoidoscopy, double contrast barium enema, or CT colonography within the past 5 years is acceptable \[see recommendations of the American Cancer Society\])~  2. Since the onset (if applicable) of any of the following alarm features for patients of any age (see Spiller and Thompson, 2010 - i.e. Patient has documented weight loss within the past 6 months; Patient has nocturnal symptoms; Patient has a familial history of colon cancer; or patient has blood mixed with their stool (excluding any blood from hemorrhoids).~4. Patient has an average daily stool consistency score (BSS) of ≥5.5 on days without the use of an anti-diarrheal and at least 3 days with a BSS score ≥5 on a 1 to 7 scale over the week prior to randomization.~5. Patient has completed the daily diary on at least 6 of the 7 days during the week prior to randomization AND at least 11 of the 14 days during the 2 weeks prior to randomization.~6. Patient has not used loperamide rescue medication more than 4 days during the screening period.~7. Patient is not planning to change his/her usual diet and lifestyle during the course of the study.~8. Patient is willing to be compliant with study procedures including completing the daily diary during the screening period and throughout the study.~9. Patient must sign an informed consent document before the initiation of any study-related procedures indicating that he or she understands the purpose of and procedures required for the study and is willing to participate in the study.~Exclusion Criteria:~1. Patient has a history of inflammatory or immune-mediated GI disorders including inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis, microscopic colitis) and celiac disease.~2. Patient has a predominant symptom of abdominal pain.~3. Patient has a history of diverticulitis within 3 months prior to screening. Patients with a history of diverticulosis are candidates for the study.~4. Patient has a history of intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, or impaired intestinal circulation (eg, aortoiliac disease).~5. Patient has any of the following surgical history:~   1. Any abdominal surgery within the 3 months prior to screening; or~  2. Patient has a history of major gastric, hepatic, pancreatic, or intestinal surgery (appendectomy, cholecystectomy, hemorrhoidectomy, or polypectomy greater than 3 months are allowed). For the purposes of this study, laparoscopic surgeries without complication are considered minor and non-exclusionary, provided the condition for which the surgery was performed was not exclusionary.~6. Patient has an unstable renal, hepatic, metabolic, or hematologic condition.~7. Patient has a history of human immunodeficiency virus infection.~8. Patient has a history of DSM-IV-TR-defined substance dependency, excluding nicotine and caffeine, within 2 years prior to Prescreening.~9. Patient has a history of alcohol abuse as defined by DSM-IV-TR, binge drinking as defined by the National Institutes on Alcohol Abuse and Alcoholism, or any medical treatment for alcohol-related co-morbidities, within 5 years prior to Prescreening. Recovered alcoholics who have not consumed alcohol over the 5 years prior to Prescreening are candidates for the study.~10. Patient has current (within 14 days of randomization) or expected use of any narcotic or opioid containing agents, tramadol~11. Patient is unable to swallow solid, oral dosage forms whole with the aid of liquid (patients may not chew, divide, dissolve, or crush the study drug).~12. Patient has received an investigational drug or used an investigational medical device within 30 days prior to randomization.~13. Patient has a known pregnancy or is breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- crofelemer (Type: EXPERIMENTAL): 125mg bid
- placebo (Type: PLACEBO_COMPARATOR): bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues